Autologous and allogeneic transplantation for T-cell lymphoma: impact of campath-1H [alemtuzumab] and soluble CD52.

Trial Profile

Autologous and allogeneic transplantation for T-cell lymphoma: impact of campath-1H [alemtuzumab] and soluble CD52.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Actual number of patients (28) added as reported by ClinicalTrials.gov record.
    • 15 Jan 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top